Litcius/Paper detail

Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma <i>via</i> AMPK-FOXO1-ULK1 signaling axis-mediated autophagy

Qiang Xiao, Hao Liu, Hongsheng Wang, Meng-Ting Cao, Xiaojun Meng, Yali Xiang, Yaqin Zhang, Feng Shu, Qiu-Gui Zhang, Hong Shan, Guanmin Jiang

2020Theranostics39 citationsDOIOpen Access PDF

Abstract

We demonstrated that HDIs triggers FOXO1-dependent autophagy, which ultimately promotes EMT, limiting the clinical outcome of HDI-based therapies. Our study suggests that the combination of an HDI and a FOXO1 inhibitor is an effective therapeutic strategy for the treatment of HCC.

Topics & Concepts

AutophagyCancer researchEpithelial–mesenchymal transitionHistone deacetylaseMetastasisIn vivoCancer cellFOXO1Cell growthBiologyChemistryCancerApoptosisSignal transductionCell biologyHistoneBiochemistryProtein kinase BGeneticsBiotechnologyGeneAutophagy in Disease and TherapyHistone Deacetylase Inhibitors ResearchSirtuins and Resveratrol in Medicine
Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma <i>via</i> AMPK-FOXO1-ULK1 signaling axis-mediated autophagy | Litcius